Michael J. O'Neill

Michael J. O'Neill publication distribution in Neuroscience in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Neuroscience in 2026. The highlighted bar marks where Michael J. O'Neill sits on this spectrum.

Michael J. O'Neill D-index placement in Neuroscience in 2026

The chart shows the D-index (discipline H-index) distribution of Neuroscience scientists ranked by Research.com in 2026. The highlighted bar marks where Michael J. O'Neill sits on this spectrum.

Best Publications

• Impaired glymphatic function and clearance of tau in an Alzheimer's disease model.

  Ian F. Harrison;Ozama Ismail;Asif Machhada;Niall Colgan;Niall Colgan

  519
  Citations

• A novel in vivo model of tau propagation with rapid and progressive neurofibrillary tangle pathology: the pattern of spread is determined by connectivity, not proximity

  Zeshan Ahmed;Jane Cooper;Tracey K. Murray;Katya Garn

  515
  Citations

• 6-Hydroxydopamine-induced Apoptosis Is Mediated via Extracellular Auto-oxidation and Caspase 3-dependent Activation of Protein Kinase Cδ

  Katharine Hanrott;Louise Gudmunsen;Michael J. O’Neill;Susan Wonnacott

  326
  Citations

• Fluoxetine-induced change in rat brain expression of brain-derived neurotrophic factor varies depending on length of treatment.

  G. de Foubert;S.L. Carney;C.S. Robinson;E.J. Destexhe

  302
  Citations

• The role of neuronal nicotinic acetylcholine receptors in acute and chronic neurodegeneration.

  M J O'Neill;T K Murray;V Lakics;N P Visanji

  279
  Citations

• AMPA Receptor Potentiators for the Treatment of CNS Disorders

  Michael J O'Neill;David Bleakman;Dennis M Zimmerman;Eric S Nisenbaum

  277
  Citations

• Conformation Determines the Seeding Potencies of Native and Recombinant Tau Aggregates

  Benjamin Falcon;Annalisa Cavallini;Rachel Angers;Sarah Glover

  274
  Citations

• Application of neurite orientation dispersion and density imaging (NODDI) to a tau pathology model of Alzheimer's disease

  Niall Colgan;Niall Colgan;Bernard Siow;James M. O'Callaghan;Ian F. Harrison

  239
  Citations

• The IMPROVE Guidelines (Ischaemia Models: Procedural Refinements Of in Vivo Experiments):

  Nathalie Percie du Sert;Alessio Alfieri;Stuard M. Allan;Hilary V. O. Carswell

  202
  Citations

• Neuroprotective activity of the potent and selective mGlu1a metabotropic glutamate receptor antagonist, (+)-2-methyl-4 carboxyphenylglycine (LY367385): comparison with LY357366, a broader spectrum antagonist with equal affinity for mGlu1a and mGlu5 receptors.

  V Bruno;G Battaglia;A Kingston;M.J O’Neill

  188
  Citations

• Antagonists of GLU K5 -containing kainate receptors prevent pilocarpine-induced limbic seizures

  Ilse Smolders;Zuner A. Bortolotto;Vernon R. J. Clarke;Ruth Warre

  183
  Citations

• LY503430, a Novel α-Amino-3-hydroxy-5-methylisoxazole-4-propionic Acid Receptor Potentiator with Functional, Neuroprotective and Neurotrophic Effects in Rodent Models of Parkinson's Disease

  Tracey K. Murray;Katherine Whalley;Christine S. Robinson;Mark A. Ward

  164
  Citations

• An AMPA receptor potentiator modulates hippocampal expression of BDNF: an in vivo study

  Marzena Mackowiak;Michael J O’Neill;Caroline A Hicks;David Bleakman

  160
  Citations

• Short Fibrils Constitute the Major Species of Seed-Competent Tau in the Brains of Mice Transgenic for Human P301S Tau.

  Samuel J. Jackson;Caroline Kerridge;Jane Cooper;Annalisa Cavallini

  159
  Citations

• Glucocerebrosidase 1 deficient Danio rerio mirror key pathological aspects of human Gaucher disease and provide evidence of early microglial activation preceding alpha-synuclein-independent neuronal cell death

  Marcus Keatinge;Hai Bui;Aswin Menke;Yu-Chia Chen

  158
  Citations

• Loss of MicroRNA-7 Regulation Leads to α-Synuclein Accumulation and Dopaminergic Neuronal Loss In Vivo.

  Kirsty J McMillan;Tracey K Murray;Nora Bengoa-Vergniory;Oscar Cordero-Llana

  156
  Citations

• Decahydroisoquinolines: novel competitive AMPA/kainate antagonists with neuroprotective effects in global cerebral ischaemia.

  Michael J O'Neill;Ann Bond;Paul L Ornstein;Mark A Ward

  149
  Citations

• The adenosine A2A antagonist KF17837 reverses the locomotor suppression and tremulous jaw movements induced by haloperidol in rats: possible relevance to parkinsonism.

  M Correa;A Wisniecki;A Betz;D.R Dobson

  145
  Citations

• Mapping the central effects of ketamine in the rat using pharmacological MRI

  Clare L. Littlewood;Nicholas Jones;Michael J. O’Neill;Stephen N. Mitchell

  141
  Citations

• Upregulation of calpain activity precedes tau phosphorylation and loss of synaptic proteins in Alzheimer's disease brain

  Ksenia Kurbatskaya;Emma Claire Phillips;Cara Louise Croft;Giacomo Dentoni

  141
  Citations

• Evaluation of the mGluR2/3 agonist LY379268 in rodent models of Parkinson's disease.

  Tracey K Murray;Marcus J Messenger;Mark A Ward;Sandra Woodhouse

  134
  Citations